Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High – Still a Buy?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares hit a new 52-week high on Thursday. The stock traded as high as $119.21 and last traded at $116.82, with a volume of 3,768,940 shares trading hands. The stock had previously closed at $109.62.

Analysts Set New Price Targets

Several analysts recently issued reports on HALO shares. Wells Fargo & Company boosted their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Citizens Jmp upped their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st. Finally, HC Wainwright raised their target price on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $96.50.

Halozyme Therapeutics Trading Up 6.6%

The firm has a market capitalization of $13.26 billion, a price-to-earnings ratio of 22.24, a P/E/G ratio of 0.41 and a beta of 0.88. The business has a 50 day moving average of $107.97 and a two-hundred day moving average of $84.24. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics’s revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts predict that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In related news, Director Matthew Posard sold 18,996 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the sale, the director directly owned 58,839 shares of the company’s stock, valued at approximately $6,339,313.86. This trade represents a 24.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This trade represents a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,852 shares of company stock valued at $13,538,046 over the last ninety days. Corporate insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several large investors have recently modified their holdings of the business. CoreCap Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 98.0% in the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 150 shares during the period. MidFirst Bank purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Halozyme Therapeutics during the second quarter valued at $28,000. Quantbot Technologies LP bought a new position in Halozyme Therapeutics in the 2nd quarter worth about $30,000. Finally, Mather Group LLC. raised its holdings in shares of Halozyme Therapeutics by 48.9% in the 3rd quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 136 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.